| Dr George Michael Elliott, MD | |
|
300 E Warwick Dr, Alma, MI 48801 | |
| (989) 331-7940 | |
| Not Available |
| Full Name | Dr George Michael Elliott |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 22 Years |
| Location | 300 E Warwick Dr, Alma, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558397638 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD 60041418 (Washington) | Secondary |
| 207P00000X | Emergency Medicine | 4301080155 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Midmichigan Medical Center-gratiot | Alma, MI | Hospital |
| Midmichigan Medical Center-clare | Clare, MI | Hospital |
| Midmichigan Medical Center - Alpena | Alpena, MI | Hospital |
| Midmichigan Medical Center-west Branch | West branch, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mymichigan Medical Center Alma | 3375451404 | 82 |
| Mymichigan Medical Center Alpena | 8527969922 | 82 |
| Mymichigan Medical Center Clare | 7012829773 | 97 |
| Mymichigan Medical Center West Branch | 7214251081 | 49 |
News Archive
A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.
Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta.
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.
Xcenda, the strategic consulting arm of AmerisourceBergen, one of the largest global pharmaceutical sourcing and distribution service companies, recently conducted the first-ever health economic analysis on coffee consumption.
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.
› Verified 3 days ago
| Entity Name | Mymichigan Medical Center Alma |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265596126 PECOS PAC ID: 3375451404 Enrollment ID: O20040202000975 |
News Archive
A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.
Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta.
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.
Xcenda, the strategic consulting arm of AmerisourceBergen, one of the largest global pharmaceutical sourcing and distribution service companies, recently conducted the first-ever health economic analysis on coffee consumption.
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.
› Verified 3 days ago
| Entity Name | Mymichigan Medical Center Alpena |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508332792 PECOS PAC ID: 8527969922 Enrollment ID: O20040415000495 |
News Archive
A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.
Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta.
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.
Xcenda, the strategic consulting arm of AmerisourceBergen, one of the largest global pharmaceutical sourcing and distribution service companies, recently conducted the first-ever health economic analysis on coffee consumption.
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.
› Verified 3 days ago
| Entity Name | Mymichigan Medical Center Clare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134394026 PECOS PAC ID: 7012829773 Enrollment ID: O20080721000628 |
News Archive
A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.
Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta.
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.
Xcenda, the strategic consulting arm of AmerisourceBergen, one of the largest global pharmaceutical sourcing and distribution service companies, recently conducted the first-ever health economic analysis on coffee consumption.
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.
› Verified 3 days ago
| Entity Name | Mymichigan Medical Center West Branch |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538566765 PECOS PAC ID: 7214251081 Enrollment ID: O20160714002424 |
News Archive
A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.
Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta.
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.
Xcenda, the strategic consulting arm of AmerisourceBergen, one of the largest global pharmaceutical sourcing and distribution service companies, recently conducted the first-ever health economic analysis on coffee consumption.
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.
› Verified 3 days ago
| Entity Name | Sound Physicians Emergency Medicine Of Michigan, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568913473 PECOS PAC ID: 6800178195 Enrollment ID: O20170120002764 |
News Archive
A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.
Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta.
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.
Xcenda, the strategic consulting arm of AmerisourceBergen, one of the largest global pharmaceutical sourcing and distribution service companies, recently conducted the first-ever health economic analysis on coffee consumption.
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr George Michael Elliott, MD Po Box 1031, Midland, MI 48641-1031 Ph: (425) 358-1795 | Dr George Michael Elliott, MD 300 E Warwick Dr, Alma, MI 48801 Ph: (989) 331-7940 |
News Archive
A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.
Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta.
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.
Xcenda, the strategic consulting arm of AmerisourceBergen, one of the largest global pharmaceutical sourcing and distribution service companies, recently conducted the first-ever health economic analysis on coffee consumption.
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.
› Verified 3 days ago
Joseph David Peterson, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 E Warwick Dr, Alma, MI 48801 Phone: 989-463-1101 | |
Samuel Robles, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 300 South Warwick Dr, Alma, MI 48801 Phone: 989-463-1101 | |
Dr. Samantha Tuczynski, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 E Warwick Dr, Alma, MI 48801 Phone: 989-466-3228 |